Epix Resubmits Vasovist Application to FDA

Xconomy Boston — 

Epix Pharmaceuticals (NASDAQ: EPIX) said today it has resubmitted an application to the Food and Drug Administration for marketing of Vasovist, and hopes to win approval to market the product in the U.S. by the end of 2008. The Lexington, MA-based company’s original application was filed in December 2003, and has been delayed by regulators’ questions and an appeal process. The product, Epix’s first in the U.S. if cleared for sale, is designed to help doctors get a clearer picture from magnetic resonance angiography tests to look at patients’ blood vessels.